Genmab — April 2023
-
En anden vinkel som ingen rigtig ville kommentere herinde, da jeg fremlagde den tidligere er, at disse tvister kommer til, at tegne nogle nye linjer for partnerskab og økonomisk ansvar. Tænker mange følger med i spænding og vil have fokus på, hvordan en agent ikke kører principal ud på et sidespor ved specielle konstruktioner for, at tørre omkostninger af på modparten, i fremtidige samarbejdsaftaler.... skrevet helt uden forbehold.
-
CONGRESS #EBMT23 | Anthony Wang,
@abbvie
presents indirect comparisons of #Epcoritamab vs CIT & axi-cel in R/R #LBCL. Epcoritamab showed significantly better ORR, CR & OS vs CIT while no significant differences vs axi-cel were observed. https://twitter.com/lymphomahub/status/1651194848731357184 -
Video - Lyt med for at høre om den manglende kurseffekt på Genmabs afvisning af voldgift mod Janssen og få kommentarer på regnskaber fra Microsoft og Google. https://www.proinvestor.com/boards/112305
-
ASCO abstract titles are out for those interested https://meetings.asco.org/abstracts-presentations
-
Godmorgen

-
I don't the full abstract was posted yet: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207 https://aacrjournals.org/cancerres/article/83/8_Supplement/CT164/725551
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind